Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
231
Recruiting, any sponsor type, condition "renal cell carcinoma"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting231
- Completed948
231 trials
Showing 1 to 25, recently updated first.
National Cancer Institute (NCI)NIH
NCT05155033 · 78 participants (planned) · Start Aug 18, 2022 · Primary completion Sep 1, 2031
Drug: Pembrolizumab; Aldesleukin · For: Metastatic Melanoma; Advanced Locoregional Melanoma; Metastatic Renal Cell Carcinoma and 1 more
Sites: Bethesda, Maryland
- DESTINY-PANTUMOUR04Recruiting
AstraZenecaAstraZeneca (AZN)
NCT07124000 · 100 participants (planned) · Start Sep 18, 2025 · Primary completion Mar 30, 2028
Drug: Trastuzumab deruxtecan · For: Adenocarcinoma (NOS); Anal Cancer; Bladder Cancer and 24 more
Sites: Birmingham, Alabama; Bullhead City, Arizona; Casa Grande, Arizona · 18 sites in all
National Cancer Institute (NCI)NIH
NCT07516366 · 16 participants (planned) · Start May 17, 2027 · Primary completion Dec 31, 2028
Drug: Balstilimab; Botensilimab · For: Clear Cell Renal Cell Carcinoma; Stage II Renal Cell Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8 and 1 more
Sites: Irvine, California; Orange, California; Gainesville, Florida · 6 sites in all
- Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07227415 · 224 participants (planned) · Start Feb 10, 2026 · Primary completion Nov 2, 2027
Drug: PF-08634404; Ipilimumab and 2 more · For: Carcinoma, Renal Cell; Advanced Renal Cell Carcinoma; Renal Cancer and 10 more
Sites: Phoenix, Arizona; Scottsdale, Arizona; Fayetteville, Arkansas · 186 sites in all
Norroy Bioscience Co., LTDIndustry
NCT07768306 · 20 participants (planned) · Start Nov 8, 2026 · Primary completion Mar 2027
Drug: 68Ga-NYM096 injection · For: Clear Cell Renal Cell Carcinoma (ccRCC)
Sites: Beijing, China
- A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsPivotal-lookingRecruiting
Arvinas Inc.Industry
NCT07749586 · 499 participants (planned) · Start Jul 29, 2026 · Primary completion Mar 31, 2031
Drug: ARV-6723; Pembrolizumab and 1 more · For: Advanced Solid Tumor
Sites: Boston, Massachusetts; New York, New York; Huntersville, North Carolina · 5 sites in all
- Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma.Recruiting
Kidney Cancer Research BureauAcademic, hospital or other
NCT07937553 · 40 participants (planned) · Start Aug 15, 2025 · Primary completion Aug 1, 2027
Drug: Lenvatinib; Pembolizumab and 1 more · For: Metastatic Chromophobe Renal Cell Carcinoma
Sites: Chelyabinsk, Russia; Krasnoyarsk, Russia; Orenburg, Russia · 8 sites in all
National Cancer Institute (NCI)NIH
NCT03866382 · 314 participants (planned) · Start May 13, 2019 · Primary completion Feb 28, 2027
Drug: Cabozantinib S-malate; Ipilimumab and 1 more · For: Bladder Adenocarcinoma; Bladder Clear Cell Adenocarcinoma; Bladder Mixed Adenocarcinoma and 42 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Kingman, Arizona · 582 sites in all
- Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on TumorsPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07863024 · 320 participants (planned) · Start Oct 28, 2026 · Primary completion Mar 10, 2031
Drug: REGN13089-M404-M2980 · For: Advanced Solid Tumors
Sites: Huntersville, North Carolina
LG ChemIndustry
NCT06332755 · 76 participants (planned) · Start Jun 5, 2024 · Primary completion Nov 2027
Drug: Phase 1a: LB-LR1109; Phase 1b: LB-LR1109 and Atezolizumab · For: Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC); Renal Cell Carcinoma(RCC) and 2 more
Sites: Fairfax, Virginia
KaliVir ImmunotherapeuticsIndustry
NCT06444815 · 60 participants (planned) · Start Sep 16, 2024 · Primary completion Sep 30, 2027
Drug: VET3-TGI; Atezolizumab · For: Solid Tumor, Adult; Microsatellite Stable Colorectal Cancer; Head and Neck Squamous Cell Carcinoma and 10 more
Sites: Los Angeles, California; Orange, California; Miami, Florida · 8 sites in all
- A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior ImmunotherapyRecruiting
Jinling Hospital, ChinaAcademic, hospital or other
NCT06255223 · 35 participants (planned) · Start Dec 15, 2023 · Primary completion Dec 1, 2027
Drug: Anti-PD-1 monoclonal antibody · For: Renal Cell Carcinoma; Radiotherapy; Immune Checkpoint Inhibitor
Sites: Nanjing, China
- A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)Pivotal-lookingRecruiting
Brian RiniAcademic, hospital or other
NCT07188896 · 120 participants (planned) · Start Apr 29, 2026 · Primary completion Nov 30, 2029
Drug: Fianlimab; Ipilimumab and 2 more · For: Advanced Renal Cell Carcinoma (aRCC); Metastatic Renal Cell Carcinoma ( mRCC); Clear Cell Renal Cell Carcinoma (ccRCC)
Sites: Washington D.C., District of Columbia; Chapel Hill, North Carolina; Cleveland, Ohio · 6 sites in all
- 68Ga- and 18F-CAIX PET Imaging StudyPivotal-lookingRecruiting
Peking University First HospitalAcademic, hospital or other
NCT07875946 · 100 participants (planned) · Start Jul 1, 2026 · Primary completion Dec 31, 2028
Drug: 68Ga-CAIX PET/CT; 18F-CAIX · For: Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma; Renal Tumor
Sites: Beijing, China
Arcus Biosciences, Inc.Industry
NCT05536141 · 512 participants (planned) · Start Oct 26, 2022 · Primary completion Mar 2029
Drug: Casdatifan; Cabozantinib and 5 more · For: Clear Cell Renal Cell Carcinoma; Solid Tumors
Sites: Birmingham, Alabama; San Diego, California; Santa Monica, California · 25 sites in all
Novelty Nobility, Inc.Industry
NCT06805825 · 67 participants (planned) · Start Feb 3, 2025 · Primary completion Aug 30, 2027
Drug: NN3201 · For: Gastrointestinal Stromal Tumors; Small-cell Lung Cancer; Adenoid Cystic Carcinoma and 4 more
Sites: Ann Arbor, Michigan; Cleveland, Ohio; Portland, Oregon · 5 sites in all
- A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07489495 · 758 participants (planned) · Start Apr 9, 2026 · Primary completion Nov 27, 2030
Drug: Belzutifan; Zanzalintinib and 1 more · For: Carcinoma, Renal Cell
Sites: Duarte, California; Irvine, California; Marietta, Georgia · 111 sites in all
Canadian Cancer Trials GroupResearch network
NCT07297667 · 30 participants (planned) · Start Aug 30, 2026 · Primary completion Dec 1, 2028
Drug: Fludarabine; Cyclophosphamide and 1 more · For: Alveolar Soft Part Sarcoma; Renal Cell Carcinoma; Triple Negative Breast Cancer
Sites: Calgary, Canada; Ottawa, Canada; Toronto, Canada · 4 sites in all
- A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07227402 · 904 participants (planned) · Start Nov 26, 2025 · Primary completion Feb 27, 2032
Drug: Belzutifan; Zanzalintinib and 1 more · For: Renal Cell Carcinoma
Sites: Anchorage, Alaska; Fullerton, California; Los Angeles, California · 129 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07023432 · 78 participants (planned) · Start Nov 17, 2025 · Primary completion Apr 14, 2028
Drug: Belzutifan · For: Active Surveillance; Clear Cell Renal Cell Carcinoma
Sites: Houston, Texas
- Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05987241 · 992 participants (planned) · Start Feb 2, 2024 · Primary completion Sep 2, 2030
Drug: Nivolumab; Relatlimab · For: Muscle Invasive Bladder Urothelial Carcinoma; Muscle Invasive Renal Pelvis Urothelial Carcinoma; Muscle Invasive Ureter Urothelial Carcinoma and 4 more
Sites: Phoenix, Arizona; Tucson, Arizona; Fayetteville, Arkansas · 505 sites in all
Pliant Therapeutics, Inc.Industry
NCT06270706 · 124 participants (planned) · Start Aug 30, 2023 · Primary completion Jun 2030
Drug: PLN-101095; PLN-101095 and 5 more · For: Advanced or Metastatic Solid Tumor
Sites: New Haven, Connecticut; Washington D.C., District of Columbia; Atlanta, Georgia · 27 sites in all
Kidney Cancer Research BureauAcademic, hospital or other
NCT07292168 · 64 participants (planned) · Start Dec 2, 2025 · Primary completion Jan 1, 2027
Drug: humanized monoclonal anti-FGFR1 antibody OM-RCA-01 · For: Renal Cell Carcinoma Metastatic; Prostate Cancer Metastatic; Non-small Cell Lung Cancer Metastatic and 2 more
Sites: Kazan', Russia; Krasnoyarsk, Russia; Moscow, Russia · 5 sites in all
- Lenvatinib And Stereotactic radiothErapy With pembRolizumab in Metastatic Kidney Cancer PatientsPivotal-lookingRecruiting
Kidney Cancer Research BureauAcademic, hospital or other
NCT07928167 · 150 participants (planned) · Start Aug 25, 2025 · Primary completion Jan 15, 2027
Drug: Lenvatinib; Pembrolizumab · For: Metastatic Renal Cell Carcinoma ( mRCC)
Sites: Kazan', Russia; Moscow, Russia; Orenburg, Russia · 8 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07187778 · 10 participants (planned) · Start Dec 19, 2025 · Primary completion Jul 19, 2027
Drug: Pembrolizumab; Belzutifan · For: Clear Cell Renal Cell Carcinoma
Sites: Ann Arbor, Michigan; Houston, Texas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.